A PHASE I/II STUDY OF AKR1C3-ACTIVATED PRODRUG OBI8208;3424 (OBI-3424) IN PATIENTS WITH RELAPSED/REFRACTORY TCELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) / T-CELL LYMPHOBLASTIC LYMPHOMA (T-LBL) Read more
Clinical, Behavioral, and Psychosocial Outcomes of Tumor Molecular Profiling in Children, Adolescents, and Young Adults Treated for Cancer Read more
A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants with Advanced Solid Tumors Read more
DAREONTM-7: A Phase I, open-label, dose escalation and expansion trial to investigate safety and tolerability of BI 764532 intravenous infusions in combination with standard of care (platinum and etoposide) in first-line treatment of patients with neuroendocrine carcinomas (NEC) Read more
A Phase 1/2a, Multicenter, Open-label Study of BMS-986490 with or without Bevacizumab in Advanced Solid Tumors Read more
An open-label, Phase I dose escalation followed by dose expansion trial in patients with advanced solid tumours to investigate safety, pharmacokinetics, and efficacy and to select the dose for further development of BI 770371 in combination with ezabenlimab Read more
A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) combinations in Adult Participants with Advanced Solid Tumors Read more
A Phase 1b Study of Gilteritinib in Participants with Locally Advanced or Metastatic NSCLC with ALK Rearrangement After Prior Treatment with an ALK Inhibitor Read more
